Inogen estimates preliminary, unaudited total revenue for the full year 2024 to be in the range of $334.5 million to $335.5 million, reflecting YOY growth of 6% and exceeding the company’s previous fu ...

Inogen . We drove a return to revenue growth, improved profitability and disciplined cost management. Achievements in the quarter included t ...

The Company will report its official fourth quarter and full year 2024 financial results after the market closes on Tuesday, ...

President and Chief Executive Officer of Inogen. “I am confident in our team’s ability to continue delivering on our commitments and providing leading devices for patients with respiratory ...

Achievements in the quarter included the launch of Rove 4 and FDA clearance for our SIMEOX 200 device which diversifies our global product offerings, all while continuing to extend our reach and ...

Inogen, Inc., a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) ...

--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq ... for patients in the U.S.,” said Kevin Smith, President and Chief Executive Officer. “By tapping into our well-established network of healthcare ...

Goleta-based Inogen, a medical technology specializing in the manufacturing of portable oxygen containers, announced Dec. 30 that it had received U.S. Food and Drug Administration clearance for the ...